Product Details

Sandoz Solifenacin

Solifenacin Succinate
10 mg
Tablet


DIN/PIN/NPN

02399040

Manufacturer

Sandoz Canada Inc.

Formulary Listing Date

2015-11-26  

Unit Price

0.3041

Amount MOH Pays

0.3041

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

G04BD08

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02277271 Vesicare 1.6892 0.3041
02397919 Teva-Solifenacin 0.3041 0.3041
02448343 Solifenacin Succinate Tablets 0.3041 0.3041
02458268 Solifenacin 0.3041 0.3041
02399040 Sandoz Solifenacin 0.3041 0.3041
02437996 Ran-Solifenacin 0.3041 0.3041
02493047 PRZ-Solifenacin 0.3041 0.3041
02417731 PMS-Solifenacin 0.3041 0.3041
02428938 Jamp Solifenacin Succinate 0.3041 0.3041
02424347 Jamp-Solifenacin 0.3041 0.3041
02446383 Auro-Solifenacin 0.3041 0.3041
02423383 Apo-Solifenacin 0.3041 0.3041
02422247 Act Solifenacin 0.3041 0.3041
02439352 Ach-Solifenacin Succinate 0.3041 0.3041
02529718 M-Solifenacin Succinate 0.3041 0.3041
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
290 Indefinite

For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

Note: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g., dementia) and those who are already using other drugs with significant anticholinergic effects (e.g., tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.

 

EAP Criteria

NO

Product Monograph

View Monograph